Bayer and Harvard Institute Extend Research for Cancer Therapies

Bayer and the Broad Institute of MIT and Harvard have recently confirmed the continuation of their collaborative research work for another five years after a successful decade-long partnership. The objective remains focused on discovering and enhancing groundbreaking cancer therapies. The primary focus of the extended agreement will be on collaborating to identify joint targets for combating cancer and advancing the discovery of innovative approaches for treating oncology. Our relentless efforts are devoted to uncovering innovative strategies for addressing this destructive illness that afflicts numerous individuals across the globe.

According to Dominik Ruettinger, M.D., Ph.D., the global head of research and early development for oncology at Bayer AG's pharmaceuticals division, our shared objective is to revolutionize the treatment options available to cancer patients by establishing a strong and enduring pipeline in the field of oncology. Bayer's partnership with the Broad Institute has already yielded three clinical oncology candidates. We are enthusiastic about our ongoing collaboration with the distinguished scientists at Broad to further the progress of promising cancer targets into clinical development. The Broad Institute and Bayer joined forces in 2013 to create a successful and enduring partnership. By combining the Broad Institute's extensive knowledge in cancer research and chemical biology with Bayer's expertise in developing small molecules and biologics drugs, the collaboration aims to push forward the field of drug discovery and develop innovative treatments for cancer. Both parties will continue their collaborative efforts to identify further investigational drugs aimed at new oncology targets and expanding treatment options.